Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Interferon beta lb

Interferon beta-la (AVONEX , Rebif ), interferon beta-lb (Betaferon ), and interferon beta (Fiblaferon ) are applied in multiple sclerosis to reduce both frequency and severity of disease incidents and for the treatment of severe viral infections. In multiple sclerosis, DFN- 3 proteins modulate the destruction of myelin in the cause of the autoimmune reaction. [Pg.411]

Interferon beta-lb - MS For use in ambulatory patients with relapsing forms of MS to reduce the frequency of clinical exacerbations. [Pg.2004]

Recommended titration (%) Interferon beta-lb dose (mg) Volume (mL)... [Pg.2005]

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et al. Effect of early versus delayed interferon beta-lb treatment on disability after a first clinical event suggestive of multiple sclerosis a 3-year follow-up analysis of the BENEFIT smdy. Lancet 2007 370(9585) 389-97. [Pg.364]

The beta-interferons, interferon beta-la and interferon beta-lb, have both immunemodulating effects. Interferon beta-lb is produced with recombinant DNA technology. In vitro interferon beta-lb is... [Pg.469]

Pharmacokinetics Interferon beta-la-. After IM administration, peak serum levels attained in 3-15 hr. Biologic markers increase within 12 hr and remain elevated for 4 days. Half-life 10 hr (IM). Interferon beta-lb Half-life 8 min-4.3 hr. [Pg.637]

Powder for Infection 22 meg (Rebif), 30 meg (Avonex), 44 meg (Rebif). Interferon beta-lb ... [Pg.637]

Relapsing-remitting multiple sclerosis Interferon beta-la-. IM 30 meg Avonex once weekly. Subcutaneous Initially 8.8 meg Rebif 3 times/wk, may increase over 4-6 wk to 44 meg Rebif 3 times/wk. Interferon beta-lb-. Subcutaneous 0.25 mg (8 million... [Pg.637]

Interferon beta-lb-. Injection site reaction (85%), headache (84%), flu-like symptoms (76%), fever (59%), pain (52%), asthenia (49%), myalgia (44%), sinusitis (36%), diarrhea, dizziness (35%), mental status changes (29%), constipation (24%), diaphoresis (23%), vomiting (21%)... [Pg.637]

Seizures occur rarely in patients taking interferon beta-lb. [Pg.637]

Biological response modifiers glatiramer acetate interferon beta-la interferon beta-lb... [Pg.618]

Paty, D.W., and D.K. Li, Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology, 1993.43(4) 662-7. [Pg.187]

F. Place in therapy Avonex has shown significant advantages over interferon beta-lb (Betaseron) in the treatment of multiple sclerosis. It is administered once a week rather than every other day, and it is not associated with the high incidence of injection site skin necrosis reported with interferon beta-lb in some studies. It appears (based on indirect comparison) at... [Pg.195]

Dosage form Betaseron is available as a sterile, lyophihzed powder for injection. After reconstitution with accompanying diluent, Betaseron vials contain 0.25 mg interferon beta-lb per ml of solution. [Pg.196]

Pharmacokinetics The bioavaUabUity of subcutaneous interferon beta-lb is 50%. In patients receiving single intravenous Betaseron doses up to 2.0 mg, increases in serum concentrations of interferon beta-lb were dose proportional. Mean serum clearance values ranged from 9.4ml/min per kg to 28.9 ml/minperkg and were independent of dose. Mean terminal elimination half-life values ranged from 8.0 minutes to 4.3 hours and mean steady-state volume of distribution values ranged from 0.25 liter/kg to 2.88 hters/kg. Three-times-a-week intravenous dosing for 2 weeks resulted in no accumulation of interferon beta-lb in the serum of patients. [Pg.197]

G. Other applications Treatment with interferon beta-lb has demonstrated therapeutic effect in patients with secondary progressive multiple sclerosis by delaying sustained neurological deterioration. It may also be effective in the treatment of Kaposi s sarcoma and malignant glioma. [Pg.197]

H. Other considerations Interferon beta-lb was designated an orphan product for use in the treatment of multiple sclerosis. Its marketing exclusivity, however, was cut short by the approval of Avonex. [Pg.197]

Interferons and cytokines Interferon beta-lb, human recombinant produced in E. coli Betaseron Lyophilized 32MIU equivalent to 0.3 mg per vial (albumin added as a stabilizer) SC... [Pg.462]

Interferons and Interferon beta-lb, Betaseron cytokines human recombinant... [Pg.488]

Interferon beta-lb [FDA USAN INN BAN] 2-166-Interferon betal (human fibroblast rednced), 17-L-serine-[CAS beta is Greek letter]... [Pg.499]

Parenteral 22, 33, 44 meg powder for IV injection Interferon beta-lb (Betaseron)... [Pg.1206]

Arnason BG Long-term experience with interferon beta-lb (Betaferon) in multiple sclerosis. J Neurol 2005 252(Suppl 3) iii28. Brown MA Antibody treatments of inflammatory arthritis. Curr Med Chem 2005 12 2943. [PMID 16378497]... [Pg.1208]

Beatseron (interferon-beta-lb) [E. coli expressed recombinant human interferon beta] Berlex, Inc. Lyophilized (0.3 mg single-dose vial)... [Pg.310]

Clear D. Anaphylactoid reaction to methyl prednisolone developing after starting treatment with interferon beta-lb. J Neurol Neurosurg Psychiatry 1999 66(5) 690. [Pg.64]

Among 700 patients with multiple sclerosis treated with interferon beta-la (n = 467) or beta-lb (n = 233), overt hyperthyroidism occurred in five patients treated with interferon-beta-lb, three of whom required withdrawal and long-term carbimazole, while there were two cases of hypothyroidism and one of goiter without thyroid... [Pg.611]

Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-lb. Arch Neurol 1997 54(9) 1169-90. [Pg.673]

McDonald ND, Pender MP. Autoimmune hypothyroidism associated with interferon beta-lb treatment in two patients with multiple sclerosis. Aust NZ J Med 2000 30(2) 278-9. [Pg.674]

Finally, certain interferons may decrease exacerbations of multiple sclerosis (MS).36 88 Specifically, interferon beta-la (Avonex) and interferon beta-lb (Betaseron) may help reduce the incidence and severity of relapses in exacerbating-remitting MS.36 64 This... [Pg.535]

Interferon beta-lb Recombinant interferon Betaseron beta-lb (Type I interferon)... [Pg.455]

See other pages where Interferon beta lb is mentioned: [Pg.438]    [Pg.118]    [Pg.136]    [Pg.2005]    [Pg.359]    [Pg.637]    [Pg.32]    [Pg.196]    [Pg.196]    [Pg.196]    [Pg.197]    [Pg.496]    [Pg.499]    [Pg.36]    [Pg.611]    [Pg.611]    [Pg.612]    [Pg.674]   
See also in sourсe #XX -- [ Pg.118 ]



SEARCH



© 2024 chempedia.info